About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

The Use of Low Molecular Weight Heparin in Hemodiafiltration

NCT00756145·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

University Hospital, Ghent

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

chronic kidney disease stade V treated with hemodiafiltration
age \>18 year
Hematocrit \> 30%

You may not be if

treatment with vitamin K antagonists
treatment with other anti-coagulants or heparin besides the heparin used during dialysis
active bleeding, infection or malignancy
heparin associated allergy
hepatic failure
trombocytopenia \< 120.000/µl

The record

StatusCompleted

PhasePhase 4

Taking part15

StartedSep 2008

UpdatedMay 14, 2015

Conditions

Chronic Kidney Disease

Where1

University Hospital Ghent
Ghent, Belgium

Clareo Health | The Use of Low Molecular Weight Heparin in Hemodiafiltration